Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Divi's Labs slips 3% on margin worries; analysts positive on growth outlook
In the March quarter, Divi's Laboratories reported net profit at ₹751 crore, as compared to ₹662 crore a year ago, up 13.4 per cent year-on-year (Y-o-Y)
Divi's Laboratories analysts remain divided on prospects after Q4 results; Check key triggers & risks
Kotak Institutional Equities, who is bearish on Divi's Laboratories, said that the stock's current valuations of 49 times its estimated price-to-earnings ratio for FY28, is already pricing in growth potential.
Six pharma stocks that should be on your radar today over various news triggers
It was a busy weekend for pharma stocks as four of them — Divi's Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results. Meanwhile, Lupin marked its entry into the Chinese market, while Glenmark Pharma's US arm settled an anti-trust litigation. Here's a look at these names in detail:
Q4 Result Live Updates: JK Cement Profit Down 8%, Revenue Rises; NTPC Profit Zooms 38%
NTPC, Divi's Laboratories, JK Cement, and Reliance Infrastructure are among the companies to report Q4 earnings today.
Divi's Laboratories Q4 profit rises 13%, beating estimates; margin slips
The board of the Hyderabad-based pharmaceutical company also recommended a final dividend of ₹30 per share for FY26.
Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announced
Divi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751 crore. Revenue from operations increased 10% to Rs 2,831 crore. The company recommended a final dividend of Rs 30 per equity share for FY26. Full-year profit after tax stood at Rs 2,568 crore.
Divi's Laboratories consolidated net profit rises 13.44% in the March 2026 quarter
Sales rise 9.52% to Rs 2831.00 crore
Accumulate Divi's Laboratories; target of Rs 6900: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Divi's Laboratories with a target price of Rs 6900 in its research report dated May 25, 2026.